메뉴 건너뛰기
Regenerative Medicine
Volumn 6, Issue 6 SUPPL., 2011, Pages 67-69
Overcoming manufacturing and scale-up challenges
Author keywords

[No Author keywords available]
Indexed keywords

BATCH PROCESS; BIOPROCESS; BIOTECHNOLOGICAL PRODUCTION; CELL THERAPY; COMMERCIAL PHENOMENA; GOOD MANUFACTURING PRACTICE; HUMAN; PRIORITY JOURNAL; PROCESSING; REGENERATIVE MEDICINE; REVIEW; SCALE UP;
EID: 80054110922     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.11.63     Document Type: Review
Times cited : (7)
References (7)
  • 1
    • 84857122500 scopus 로고    scopus 로고
    • Office for Life Sciences, Department for Business Innovation and Skills and Department of Health, UK, URN 11/1056, □ Stock take of regenerative medicine in the UK, highlighting the technological, regulatory and strategic barriers to realizing regenerative medicine's potential
    • Office for Life Sciences. Taking Stock of Regenerative Medicine in the United Kingdom. Department for Business Innovation and Skills and Department of Health, UK, URN 11/1056 (2011). □ Stock take of regenerative medicine in the UK, highlighting the technological, regulatory and strategic barriers to realizing regenerative medicine's potential.
    • (2011) Taking Stock of Regenerative Medicine in the United Kingdom
  • 2
    • 27944510690 scopus 로고    scopus 로고
    • Why tissue engineering needs process engineering
    • □ Describes where we were in 2005
    • Archer R, Williams DJ. Why tissue engineering needs process engineering. Nat. Biotechnol. 23(11), 1353-1355 (2005). □ Describes where we were in 2005.
    • (2005) Nat. Biotechnol. , vol.23 , Issue.11 , pp. 1353-1355
    • Archer, R.1    Williams, D.J.2
  • 3
    • 78650698712 scopus 로고    scopus 로고
    • Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells
    • □ Careful analysis of both the individual treatment and system costs of alternative cell therapies
    • Bart T. Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells. Clinicoecon. Outcomes Res. 2, 141-147 (2010). □ Careful analysis of both the individual treatment and system costs of alternative cell therapies.
    • (2010) Clinicoecon. Outcomes Res. , vol.2 , pp. 141-147
    • Bart, T.1
  • 4
    • 28844487530 scopus 로고    scopus 로고
    • Banking on human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching
    • □ Estimates the number of cells required to create a bank of cells capable of reaching a national population
    • Taylor C, Bolton E, Pocock S, Sharples L, Pedersen R, Bradley J. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366, 2019-2025 (2005). □ Estimates the number of cells required to create a bank of cells capable of reaching a national population.
    • (2005) Lancet , vol.366 , pp. 2019-2025
    • Taylor, C.1    Bolton, E.2    Pocock, S.3    Sharples, L.4    Pedersen, R.5    Bradley, J.6
  • 5
    • 77952536406 scopus 로고    scopus 로고
    • Challenges in characterising and quantifying cell-and tissue-based therapies for clinical translation
    • □ Perspective on the issues in characterizing cell therapies
    • Rayment E, Williams DJ. Challenges in characterising and quantifying cell-and tissue-based therapies for clinical translation. Stem Cells 28, 996-1004 (2010). □ Perspective on the issues in characterizing cell therapies.
    • (2010) Stem Cells , vol.28 , pp. 996-1004
    • Rayment, E.1    Williams, D.J.2
  • 6
    • 79952692531 scopus 로고    scopus 로고
    • Threedimensional culture and bioreactors for cellular therapies
    • □ Translational review of progress in 3D culture systems
    • Naing MW, Williams DJ. Threedimensional culture and bioreactors for cellular therapies. Cytotherapy 13(4), 391-399 (2011). □ Translational review of progress in 3D culture systems.
    • (2011) Cytotherapy , vol.13 , Issue.4 , pp. 391-399
    • Naing, M.W.1    Williams, D.J.2
  • 7
    • 79955140577 scopus 로고    scopus 로고
    • Cell therapy bioprocessing, integrating process and product development for the next generation of biotherapeutics
    • □ An industry and academic perspective of bioprocessing challenges from the Process and Product Development subcommittee of the International Society of Cell Therapy
    • Brandenberger R, Burger R, Campbell A, Fong T, Lapinskas E, Rowley JA. Cell therapy bioprocessing, integrating process and product development for the next generation of biotherapeutics. Bioprocess Int. 9(3), S30-S37 (2011). □ An industry and academic perspective of bioprocessing challenges from the Process and Product Development subcommittee of the International Society of Cell Therapy.
    • (2011) Bioprocess Int. , vol.9 , Issue.3
    • Brandenberger, R.1    Burger, R.2    Campbell, A.3    Fong, T.4    Lapinskas, E.5    Rowley, J.A.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.